Advanced

Tamoxifen treated patients have a better survival than patients treated with aromatase inhibitors - A population based registry study in Sweden

H., Olsson LU ; Einefors, R and P., Broberg LU (2015) 37th San Antonio Breast Cancer Symposium In Cancer Research 75(9 Suppl).
Abstract
Background. Randomised trials suggest that therapy with aromatase inhibitors improves survival in breast cancer compared with tamoxifen therapy in postmenopausal cases with hormone receptor positive breast cancer. Whether these results from randomized studies transform into the general population is unknown. We have therefore compared survival for all breast cancer cases in Sweden diagnosed 2000-2008 (n=54406) who received adjuvant antihormonal therapy. Material and methods. The study includes all women with BC diagnosed in Sweden between 2000 through 2008 (n=54406). The women had no previous cancer diagnosis during the period of 1958-1999. Dates of birth, BC diagnosis and TNM-stage where directly extracted from the cancer registry. The... (More)
Background. Randomised trials suggest that therapy with aromatase inhibitors improves survival in breast cancer compared with tamoxifen therapy in postmenopausal cases with hormone receptor positive breast cancer. Whether these results from randomized studies transform into the general population is unknown. We have therefore compared survival for all breast cancer cases in Sweden diagnosed 2000-2008 (n=54406) who received adjuvant antihormonal therapy. Material and methods. The study includes all women with BC diagnosed in Sweden between 2000 through 2008 (n=54406). The women had no previous cancer diagnosis during the period of 1958-1999. Dates of birth, BC diagnosis and TNM-stage where directly extracted from the cancer registry. The women's antihormonal therapy was gathered from the Swedish Prescription Registry (22213 women were on antihormonal therapy). Information regarding the cause of death and date of death was obtained from the Cause of Death Registry and tbe Swedish Population Register up until the 31st of December 2012 and 31st of December 2013 respectively. The breast cancer death and overall death have been calculated and the survival was compared between tamoxifen and aromatase inhibitor treated breast cancer patients. Analyses were adjusted for TNM-stage and age at diagnosis and restricted to women aged 50 and above. Results. Patients being treated with tamoxifen had a better breast cancer prognosis compared with aromatase inhibitor treated patients (HR 0.54, 95%CI 0.48-0.61). Restricting the analysis to stage 1 disease confirmed a better prognosis for tamoxifen treated women (HR 0.48, 95%CI 0.34-0.66). A better prognosis could be seen in all age strata studies, 50-60.61-70.71-90. The findings for overall survival gave similar results. Conclusion .This population based observational study show that women treated with aromatase inhibitors have a worse overall and breast cancer specific survival compared with tamoxifen treated women regardless of age and tumor stage. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
aromatase inhibitor, tamoxifen, adjuvant, hormone receptor, human, patient, survival, register, population, Sweden, breast cancer, female, therapy, death, cause of death, cancer staging, diagnosis, prognosis, cancer prognosis, cancer patient, cancer mortality, prescription, cancer registry, cancer specific survival, cancer diagnosis, observational study, overall survival
in
Cancer Research
volume
75
issue
9 Suppl
publisher
American Association for Cancer Research Inc.
conference name
37th San Antonio Breast Cancer Symposium
conference location
San Antonio, Texas, United States
conference dates
2014-12-09 - 2014-12-13
ISSN
0008-5472
DOI
10.1158/1538-7445.SABCS14-P1-12-10
language
English
LU publication?
yes
id
9ef93d8c-7806-40fa-9119-bc6dde8364a8
date added to LUP
2019-07-01 11:41:09
date last changed
2019-07-01 11:41:09
@misc{9ef93d8c-7806-40fa-9119-bc6dde8364a8,
  abstract     = {Background. Randomised trials suggest that therapy with aromatase inhibitors improves survival in breast cancer compared with tamoxifen therapy in postmenopausal cases with hormone receptor positive breast cancer. Whether these results from randomized studies transform into the general population is unknown. We have therefore compared survival for all breast cancer cases in Sweden diagnosed 2000-2008 (n=54406) who received adjuvant antihormonal therapy. Material and methods. The study includes all women with BC diagnosed in Sweden between 2000 through 2008 (n=54406). The women had no previous cancer diagnosis during the period of 1958-1999. Dates of birth, BC diagnosis and TNM-stage where directly extracted from the cancer registry. The women's antihormonal therapy was gathered from the Swedish Prescription Registry (22213 women were on antihormonal therapy). Information regarding the cause of death and date of death was obtained from the Cause of Death Registry and tbe Swedish Population Register up until the 31st of December 2012 and 31st of December 2013 respectively. The breast cancer death and overall death have been calculated and the survival was compared between tamoxifen and aromatase inhibitor treated breast cancer patients. Analyses were adjusted for TNM-stage and age at diagnosis and restricted to women aged 50 and above. Results. Patients being treated with tamoxifen had a better breast cancer prognosis compared with aromatase inhibitor treated patients (HR 0.54, 95%CI 0.48-0.61). Restricting the analysis to stage 1 disease confirmed a better prognosis for tamoxifen treated women (HR 0.48, 95%CI 0.34-0.66). A better prognosis could be seen in all age strata studies, 50-60.61-70.71-90. The findings for overall survival gave similar results. Conclusion .This population based observational study show that women treated with aromatase inhibitors have a worse overall and breast cancer specific survival compared with tamoxifen treated women regardless of age and tumor stage.},
  articleno    = {Abstract P1-12-10},
  author       = {H., Olsson and Einefors, R and P., Broberg},
  issn         = {0008-5472},
  keyword      = {aromatase inhibitor,tamoxifen,adjuvant,hormone receptor,human,patient,survival,register,population,Sweden,breast cancer,female,therapy,death,cause of death,cancer staging,diagnosis,prognosis,cancer prognosis,cancer patient,cancer mortality,prescription,cancer registry,cancer specific survival,cancer diagnosis,observational study,overall survival},
  language     = {eng},
  location     = {San Antonio, Texas, United States},
  note         = {Conference Abstract},
  number       = {9 Suppl},
  publisher    = {American Association for Cancer Research Inc.},
  series       = {Cancer Research},
  title        = {Tamoxifen treated patients have a better survival than patients treated with aromatase inhibitors - A population based registry study in Sweden},
  url          = {http://dx.doi.org/10.1158/1538-7445.SABCS14-P1-12-10},
  volume       = {75},
  year         = {2015},
}